Durvalumab (D) plus /- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial

被引：7

作者：

Thibault, C. ^{[1
]}

Bennamoun, M. ^{[2
]}

Flechon, A. ^{[3
]}

Gravis, G. ^{[4
]}

Pouessel, D. ^{[5
]}

Combe, P-F. ^{[6
]}

Borchiellini, D. ^{[7
]}

Loriot, Y. ^{[8
]}

Laguerre, B. ^{[9
]}

Barthelemy, P. ^{[10
]}

Goupil, M. Gross ^{[11
]}

Helissey, C. ^{[12
]}

Huillard, O. ^{[13
]}

Cancel, M. ^{[14
]}

Campedel, L. ^{[15
]}

Audenet, F. ^{[16
]}

Belhouari, H. ^{[17
]}

Kotti, S. ^{[17
]}

Tran, Y. ^{[18
]}

Oudard, S. ^{[1
]}

机构：

[1] HEGP, AP HP, Med Oncol Dept, Paris, France

[2] Inst Mutualiste Montsouris, Oncol, Paris, France

[3] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[4] IPC, Dept Med Oncol, Immun & Canc Team, Marseille, France

[5] Oncopole Claudius Regaud Inst Univ Canc, Dept Med Oncol, Toulouse, France

[6] Pole Sante Leonard de Vinci, Oncol, Chambray Les Tours, France

[7] Ctr Anticanc Antoine Lacassagne, Dept Med Oncol, Nice, France

[8] Inst Gustave Roussy, DITEP, Villejuif, France

[9] Ctr Eugene Marquis, Med Oncol, Rennes, France

[10] ICANS Inst Cancerol Strasbourg Europe, Dept Med Oncol, Strasbourg, France

[11] CHU Bordeaux Hop St Andre, Dept Med Oncol, Bordeaux, France

[12] Mil Hosp Begin, Clin Res Unit, St Mande, France

[13] Hop Cochin, AP HP, Cancerol, Paris, France

[14] Univ Hosp Tours, Dept Med Oncol, Tours, France

[15] Hop La Pitie Salpetriere, Dept Med Oncol, Paris, France

[16] HEGP, AP HP, Paris, France

[17] ARTIC, Med Oncol, Paris, France

[18] ARTIC, Stat, Paris, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2364MO

引用

页码：S1202 / S1202

页数：1

共 38 条

[21] Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC). [J].

Rose, Tracy L. ;

Harrison, Michael Roger ;

Deal, Allison Mary ;

Osterman, Chelsea K. ;

Ramalingam, Sundhar ;

Whang, Young E. ;

Brower, Blaine Y. ;

Bjurlin, Marc ;

Smith, Angela B. ;

Nielsen, Matthew E. ;

Tan, Hung-Jui ;

Wallen, Eric M. ;

George, Daniel J. ;

Zhang, Tian ;

Drier, Anthony ;

Kim, William Y. ;

Milowsky, Matthew, I .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[22] Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676) [J].

Necchi, Andrea ;

Giannatempo, Patrizia ;

Mariani, Luigi ;

Fina, Emanuela ;

Nicolai, Nicola ;

Pennati, Marzia ;

Zaffaroni, Nadia ;

Fare, Elena ;

Piva, Luigi ;

Biasoni, Davide ;

Catanzaro, Mario ;

Torelli, Tullio ;

Stagni, Silvia ;

Maffezzini, Massimo ;

Colecchia, Maurizio ;

Paolini, Biagio ;

Cappelletti, Vera ;

Daidone, Maria Grazia ;

Gianni, Alessandro M. ;

Salvioni, Roberto .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)

[23] A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates [J].

Choueiri, Toni K. ;

Jacobus, Susanna J. ;

Qu, Angela Q. ;

Sweeney, Christopher ;

Appleman, Leonard Joseph ;

Tretter, Christopher P. G. ;

Bubley, Glenn J. ;

Elfiky, Aymen ;

Park, Rachel ;

Stack, Edward C. ;

Signoretti, Sabina ;

Walsh, Meghara K. ;

Steele, Graeme ;

Hirsch, Michelle S. ;

Krajewski, Katherine Maragaret ;

Taplin, Mary-Ellen ;

Rosenberg, Jonathan E. ;

Ross, Robert W. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)

[24] A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). [J].

Powles, Thomas ;

Meeks, Joshua J. ;

Galsky, Matt D. ;

Van der Heijden, Michiel Simon ;

Nishiyama, Hiroyuki ;

Al-Ahmadie, Hikmat A. ;

Goluboff, Erik T. ;

Hois, Stephan ;

Donegan, Sarah E. ;

Williams, Vanessa ;

Xiao Feng ;

Catto, James W. F. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[25] Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial [J].

Pfister, Christian ;

Gravis, Gwenaelle ;

Flechon, Aude ;

Chevreau, Christine ;

Mahammedi, Hakim ;

Laguerre, Brigitte ;

Guillot, Aline ;

Joly, Florence ;

Allory, Yves ;

Harter, Valentin ;

Culine, Stephane .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)

[26] Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. [J].

Pfister, Christian ;

Gravis, Gwenaelle ;

Flechon, Aude ;

Chevreau, Christine ;

Mahammedi, Hakim ;

Laguerre, Brigitte ;

Guillot, Aline ;

Joly, Florence ;

Allory, Yves ;

Harter, Valentin ;

Culine, Stephane .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) :LBA4507-LBA4507

[27] Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. [J].

Sheng, Xinan ;

Zhang, Cuijian ;

Ji, Yongpeng ;

Zhou, Li ;

Zou, Benkui ;

Huang, Hang ;

Wang, Yonghua ;

Yang, Kaiwei ;

Bai, Xue ;

Feng, Dan ;

Yang, Yong ;

Bian, Jiasheng ;

Yu, Zhixian ;

Niu, Haitao ;

Du, Peng ;

Fang, Jianmin ;

He, Zhisong ;

Guo, Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)

[28] A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). [J].

Gao, Jianjun ;

Siefker-Radtke, Arlene O. ;

Navai, Neema ;

Campbell, Matthew T. ;

Tidwell, Rebecca Slack ;

Guo, Charles ;

Kamat, Ashish M. ;

Matin, Surena F. ;

Araujo, John C. ;

Shah, Amishi Yogesh ;

Msaouel, Pavlos ;

Blando, Jorge M. ;

Vence, Luis M. ;

Duan, Fei ;

Basu, Sreyashi ;

Singh, Shalini ;

Zhao, Hao ;

Allison, James Patrick ;

Dinney, Colin P. N. ;

Sharma, Padmanee .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[29] Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination? Results From a Phase II Trial Combining Epirubicin and Cyclophosphamide Followed by Paclitaxel and Gemitabine ± Trastuzumab in Stage II and III Breast Cancer Patients [J].

Sanchez-Munoz, Alfonso ;

Duenas-Garcia, R. ;

Jaen-Morago, A. ;

Carrasco, E. ;

Chacon, I. ;

Garcia-Tapiador, A. M. ;

Ortega-Granados, A. L. ;

Martinez-Ortega, E. ;

Ribelles, N. ;

Fernandez-Navarro, M. ;

de la Torre-Cabrera, C. ;

Duenas, B. ;

Rueda, A. I. ;

Martinez, J. ;

Ramirez Tortosa, C. ;

Martin-Salvago, M. D. ;

Sanchez-Rovira, P. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (05) :432-437

[30] Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20 [J].

Rexer, Heidrun ;

Kuebler, Hubert ;

Retz, Margitta .

AKTUELLE UROLOGIE, 2021, 52 (03) :220-221

← 1 2 3 4 →